Observational Cohort Study of TachoSil (TC-018-IN)

• Status: Completed
• Trial end date: 2008-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to collect information, after exposure to TachoSil ®, of all thromboembolic events, immunological events and drug interactions leading to thromboembolic events or major bleeding. In addition, pharmacoeconomic data will be collected.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nycomed
• Treatments: Thrombin

Criteria

Inclusion Criteria:

• All subjects, treated with TachoSil ® by the participating physicians, will be registered with a set of basic data from their already existing data (i.e. no additional diagnostic procedures will be performed).

• Subjects who will provide their written informed consent to use existing data, allow direct access to data and data processing.